Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Y0001388

Candesartan cilexetil

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, TCV 116, TCY 116

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C33H34N6O6
Número CAS:
Peso molecular:
610.66
Número MDL:
Código UNSPSC:
41116107
ID de substância PubChem:
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

candesartan

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

chave InChI

GHOSNRCGJFBJIB-UHFFFAOYSA-N

Informações sobre genes

human ... AGTR1(185)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Candesartan cilexetil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Pictogramas

Health hazard

Palavra indicadora

Danger

Frases de perigo

Classificações de perigo

Repr. 1B - STOT RE 2 Oral

Órgãos-alvo

Kidney,Blood

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Greg L Plosker et al.
PharmacoEconomics, 24(12), 1249-1272 (2006-11-30)
The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis
Gerd Bönner et al.
Current medical research and opinion, 21(6), 935-940 (2005-06-23)
Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. This short review summarises results of clinical studies focusing on the duration of action of candesartan cilexetil. Results of previous clinical studies indicate that candesartan
G Mancia et al.
Journal of human hypertension, 14 Suppl 2, S3-10 (2000-11-22)
The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for
Peter A Meredith
Current medical research and opinion, 23(7), 1693-1705 (2007-06-26)
Therapeutic interventions that block the renin-angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an
Naoki Ichikawa et al.
Neurological research, 37(2), 147-152 (2014-08-05)
The purpose of this study was to examine whether oral administration of an angiotensin II type 1 receptor blocker (ARB) inhibited in-stent neointimal hyperplasia in carotid arteries of hypercholesterolemic rabbits. Eleven male New Zealand white rabbits were subjected to endothelial

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica